Trials and Fibrillations with Dr John Mandrola

 
 

Trials and Fibrillations with Dr John Mandrola

  • Lessons From the Save of Christian Eriksen's Life The Danish soccer star went from 'being gone' to resuscitated. His widely watched experience teaches many lessons about improving care for sudden cardiac death, a major public health problem.
  • ACC 2021 Renal Denervation for Resistant Hypertension Is Not Back on Track The RADIANCE-HTN-TRIO presentation at the recent American College of Cardiology meeting has this cardiologist asking if mineralocorticoid inhibition might beat an invasive procedure for resistant hypertension.
  • ACC 2021 PARADISE-MI Makes Me Question the Benefits of Sacubitril/Valsartan Sacubitril valsartan (Entresto), deemed 'the Big E' by some clinicians, has fallen short in 2 of 3 clinical trials. The latest, presented at the ACC 2021 scientific session, is PARADISE-MI.
  • ACC 2021 Eight Things to Know About the LAAOS III Trial The trial, showing a benefit for surgical left appendage occlusion in patients with AF undergoing cardiac surgery, should change practice, but there are caveats, notes John Mandrola, MD.
  • Mandrola Previews (Virtual) ACC 2021 Presentations on aspirin dosing, surgical left atrial appendage occlusion, heart failure rehab, and rate vs rhythm control are among the top picks from the virtual ACC 2021, according to John Mandrola, MD.
  • A Tribute to Bernard Lown There are lessons for us all in the life and legacy of the renowned cardiologist and peace activist Bernard Lown, notes John Mandrola, MD.
  • Colchicine Post-MI: Close but No Cigar The inflammatory hypothesis of coronary artery disease has gained traction, but prescribing drugs with anti-inflammatory effects has yet to take off. Could recent data on colchicine change that?
  • Five Reasons Sacubitril/Valsartan Should NOT Be Approved for HFpEF The pricey drug Entresto is approved for heart failure with reduced ejection fraction, but should it also get an indication for HF with preserved ejection fraction? Cardiologist John Mandrola, MD, says no.
  • Mandrola's Top 10 in Cardiology for 2020 While the pandemic dominated the medical news, there were both exciting and concerning developments in the world of cardiology.
  • AHA 2020 EARLY-AF and STOP AF Put Electrophysiology at a Crossroads Seemingly positive data on earlier use of catheter ablation in patients with atrial fibrillation concerns some electrophysiologists.
  • AHA 2020 SAMSON Answers the Statin Side Effect Question A nifty trial presented at the American Heart Association meeting could help patients with statin side effects restart the drugs.
  • Mandrola Previews AHA 2020 A trial that aims to answer whether statin myalgia is drug related tops the picks. Studies on CT angiography, AF monitoring, fish oils, and a novel MRA will also feature at the 2020 American Heart Association meeting.
  • Latest EXCEL MI Analysis Settles Nothing; Flaws Remain A new analysis from the trial comparing stents and surgery in patients with left main coronary artery disease obfuscates and distracts from the core flaws of EXCEL and its interpretation, says John Mandrola, MD.
  • The PRAETORIAN Trial: Guarded Approach to Subcutaneous ICD Best Defibrillation without the downsides is the promise of the S-ICD because there are no leads in the veins and heart. But is one RCT enough to trust this technology to prevent sudden cardiac death?
  • ESC 2020 Seven Quick Thoughts on the New European AF Guidelines There's much to admire in the new ESC/EACTS guidelines on atrial fibrillation, but the push for opportunistic screening concerns electrophysiologist John Mandrola, MD.
  • ESC 2020 EAST-AFNET 4 Favors Rhythm Control, but It's Complicated Electrophysiologist John Mandrola, MD, cautions against oversimplifying the results of EAST-AFNET 4 to mean use more anti-arrhythmic drugs or do more ablation.
  • ESC 2020 Digoxin Stuns in RATE-AF Trial A drug with a bad rap in the U.S. outperforms usual practice in patients with permanent AF. Are the results convincing enough to persuade a slow-medicine practitioner like John Mandrola, MD?
  • Mandrola Previews the Virtual ESC 2020 Trials on SGLT2 inhibitors, rhythm control in AF, and a few drugs he’s never heard of are among John Mandrola’s picks from the upcoming European Society of Cardiology Congress.
  • LAAO vs DOAC: PRAGUE-17 Falls Short A comparison of left atrial appendage closure and direct oral anticoagulants for stroke prevention in atrial fibrillation exposes the holes in noninferiority trial design, writes John Mandrola, MD.
  • Let's Not Move at a Rapid Clip to Repair the Forgotten Valve Before we expand percutaneous repair of the forgotten valve with the CE-marked TriClip or off-label use of MitraClip, don't forget about the randomized trial, cautions John Mandrola, MD.